Industrial research has contributed greatly to the growth of the American economy over the past 100 years, and the domestic pharmaceutical industry, heavily research oriented, has led the world in the introduction of new drugs. However, technological innovation including new drug development in the U.S. has faltered over the last 10 years. Davis 1 observes that the challenge now is to renew this prime source of industrial strength of the country through a synthesis utilizing the characteristic strengths of industry, academia, and government. To bring this about long-range investments by industry are required, as well as stable, realistic policies by governments to encourage such investments. He notes that industrial research is at the threshold of a new era, but that a new synthesis of national, corporate, and academic resources to sustain innovation is essential. However the broadened and modified interplay between the public and private sectors takes place, it will have a pervasive influence on the nature of pharmaceutical research undertaken by the drug industry and ultimately on the project/program selection process.